landmarknew treatment
Canakinumab FDA-approved for FMF (CLUSTER trial)
Familial Mediterranean Fever →Summary
In 2016, canakinumab became the first FDA-approved biologic for colchicine-resistant FMF based on the pivotal CLUSTER trial. The trial demonstrated that canakinumab achieved complete control of disease flares in 61% of FMF patients versus 6% with placebo, establishing IL-1 blockade as an evidence-based second-line therapy.
Related treatments
More from Familial Mediterranean Fever
significantTreatment update
JAK inhibitors (tofacitinib) emerging as potential third-line therapy
significantTreatment update
IL-1 blockade established as standard second-line therapy for colchicine-resistant FMF
significantTreatment update
EULAR/PReS 2024 updated management recommendations published
significantNew research
Colchicine resistance mechanisms linked to pyrin inflammasome microtubule independence
ID: familial-mediterranean-fever-update-7Type: new_treatmentImpact: landmark